Despite significant advances in antiviral drug development during the past two decades, viral infections continue to cause serious morbidity and mortality world-wide. Diverse antiviral drugs are now available for the treatment of infections by HIV, herpes-, influenza, hepatitis B or hepatitis C viruses. Except for the broad antiviral agent ribavirin, there is no approved therapy for diverse emerging RNA viruses. In addition, new antiviral molecules are required to tackle the problems of drug toxicity and rapid development of drug resistance, which is particularly problematic for mutation-prone RNA viruses. Since virus replication occurs within host cells, and host cell metabolism and viral replication are tightly integrated, the development of compounds which selectively interfere with virus-specific process is one of the main challenges in antiviral drug design.
RESULTS AND DISCUSSION
The target compounds were prepared from 2-[6-(phenyl/4-chlorophenyl)imidazo [2,1-b] thiazol-3-yl]acetohydrazides (C/D) [37] , by a five step synthesis as shown in Figure 1 . By heating ethyl (6-(phenyl/4-chlorophenyl)imidazo [2,1-b] thiazol-3-yl)acetate hydrobromides (A/B) and hydrazine-hydrate in ethanol, 2-[6-(phenyl/4-chlorophenyl)imidazo [2,1-b] thiazol-3-yl]acetohydrazides were obtained. Hydrazides and alkyl/aryl isothiocyanates were heated in ethanol to yield 4-alkyl/aryl-1-[(6-(phenyl/4-chlorophenyl)imidazo [2,1-b] thiazol-3-yl)acetyl]-3-thiosemicarbazides E1-14 [38, 39] . The thiosemicarbazides were then reacted with ethyl α-bromoacetate/ethyl 2-bromopropionate in the presence of anhydrous sodium acetate in absolute ethanol to yield 3-alkyl/aryl-2-[((6-(phenyl/4-chlorophenyl)imidazo [ The yields and melting points of the compounds are given in Table 1 . The structures of the obtained compounds were elucidated by spectral data. 4-Thiazolidinones 1-14 obtained from thiosemicarbazide gave absorption bands at 198-202 and 257-263 nm in UV spectra. In the IR spectra, some significant stretching bands due to N-H and C=O were observed at 3107-3257 cm -1 and 1635-1695 cm -1 , respectively. A new strong band at 1695-1751 cm -1 (in some compounds two bonds [40] due to isomers) in the spectra of 1-14 provided firm support for ring closure [41] . 1 H-NMR and 13 C-NMR data were also in agreement with the formation of 4-thiazolidinone ring. NH signals of 1-14 appeared at δ 10.06-11.37 ppm. The exocyclic methylene protons of 4-6 and 10-13 displayed two singlets at δ 3.86-3.88 and δ 4.06-4.10 ppm or multiplets at δ 3.97-4.14 ppm for 1-3, 7-9 and 14 indicating the presence of two isomers in unequal proportions in DMSO-d6. This may be explained on the basis of the difference in the relative stability of the E and Z isomers formed due to the rotational restriction about the exocyclic N=C bond at position 2 of the 4-thiazolidinone ring [38, 39] . In the 1 H-NMR spectra of compounds 4-9, 11-14, CH-CH3 protons appeared as a quartet (1H) at δ 4.37-4.53 ppm and CH-CH3 protons appeared as a doublet (3H) at δ 1.51-1.57 ppm which proved the closure of 4-thiazolidinone ring [42] . On the other hand, peak resonated at δ 43.24; 43.64, δ 157.16 and δ 174.25; 174.75 ppm in the 13 C-NMR (APT), 13 C-NMR (DEPT) and 1 H- 13 C HSQC NMR spectrum of compound 3-ethyl-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (4), assigned for S-CH, C=N and C=O moieties, confirms the carbon skeleton of 4-thiazolidinone ring. These peaks were observed at δ 40.42; 40.48, δ 151.82; 152.10 and δ 172.47; 172.62 ppm in the 13 C-NMR (APT) spectrum of compounds 14. ESI (+) MS of the selected compounds 4 displayed protone molecular ion [M+1] + at m/z 414 which confirmed molecular weight.
The synthesized compounds were evaluated against a broad and diverse panel of RNA-and DNAviruses using cytopathic effect (CPE) reduction assays in appropriate cell culture models (see Experimental Section for the full list of viruses). As shown in Table 2 , compound 6 had moderate activity against vesicular stomatitis virus (VSV) with an antiviral EC50 value of 9 µM and selectivity index (SI: ratio of cytotoxic to antiviral concentration) of 11. Compound 11 displayed an antiviral EC50 value of 2 µM against VSV as well as respiratory syncytial virus (RSV), with a SI of 10. For 14, anti-RSV activity was 5-fold lower but the SI was again 10. These three molecules (i.e., 6, 11 and 14) all have a methyl substituent at position R2. Evaluation of the compounds against influenza virus (Table 3) revealed that some compounds displayed weak activity as visible by CPE or MTS assay. Compound 13 (which again carries a methyl at R2) was the only one in the series with equal activity in the CPE and MTS assays, and its activity was consistent for three different strains of influenza A virus belonging to two subtypes (H1N1 and H3N2). However, its EC50 values were rather high (in the range of 60 µM). Finally, compound 7 displayed weak activity against adenovirus (EC50: 42 µM; data not shown), but not against any other DNA-virus tested. Neither of the synthesized compounds was found active against HIV-1 or -2. In combination, these antiviral data suggested that the 5-methylsubstituted thiazolidinone derivatives were more active than their nonsubstituted counterparts. The diverse virus testing panel allowed to estimate the cytotoxicity of the compounds in various mammalian cell lines (Table 4) . Most were not cytotoxic at 100 µM, the highest concentration tested. Compound 9 was the only compound showing cytotoxicity in all cell lines examined; depending on the cell line, its cytotoxic concentrations varied between 4 and 100 µM. 
CONCLUSION
In conclusion, we synthesized a series of imidazo[2,1-b]thiazoles bearing 4-thiazolidinone moieties. The new compounds were characterized by UV, IR, NMR spectra, mass spectra as well as elemental analyses. Antiviral activity testing revealed that some of the compounds exhibited antiviral activity against diverse RNA viruses (cytotoxic concentrations range of >100-20 µM). In order to improve the antiviral potency, chemical synthesis of additional thiazolidinone fused imidazo[2,1-b]thiazoles is warranted.
MATERIALS AND METHODS

Chemistry
Melting points were determined by using a Büchi B-540 melting point apparatus in open capillary tubes and are uncorrected. Elemental analyses were performed on a Thermo Finnigan Flash EA 1112 elemental analyzer. IR spectra were recorded on KBr discs, using a Shimadzu IR Affinity-1 FT-IR spectrophotometer. 1 H-NMR, 13 C-NMR (APT), 13 C-NMR (DEPT) and HSQC ( 1 H-13 C) spectra were measured on a Varian UNITY INOVA (500 MHz) spectrometer using DMSO-d6 . Mass spectra were recorded on a Thermo Finnigan LCQ Advantage Max instrument. The starting materials were either commercially available or synthesized according to the references cited. 1 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 2 >100 ≥100 >100 >100 >100 >100 >100 24 >100 >100 3 >100 >100 >100 >100 >100 32 >100 >100 >100 >100 4 >100 ≥100 20 <0.80 >100 >100 >100 >100 >100 >100 5 >100 ≥100 >100 >100 >100 >100 >100 >100 >100 >100 6 >100 ≥100 >100 >100 >100 >100 >100 >100 >100 >100 7 ≥83 100 >100 >100 >100 >100 >100 6.5 >100 >100
4.8 4.0 >100 >100 >100 >100 >100 >100 >100 >100 10 >100 ≥100 >100 >100 >100 >100 >100 50 >100 >100 11 74 73 >100 >100 >100 >100 >100 >100 >100 >100 12 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Preparation of ethyl (6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetate hydrobromides (A, B)
These compounds were obtained according to the procedure described by Robert et al [43] .
Preparation of 2-[6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl]acetohydrazides (C, D)
These compounds were prepared according to the procedure described by Kuhmstedt et al [44] .
Preparation of 4-alkyl/aryl-1-[(6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl]-3-thiosemicarbazides (E1-14)
To a solution of 2-[6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazole-3-yl]acetohydrazides (A) (0.005 mol) in ethanol (30 mL) were added the appropriate isothiocyanate (0.005 mol). The resulting mixture was heated under reflux for 3 h. After cooling, the precipitate was separated and purified by washing with hot ethanol.
General procedure for preparation of 3-alkyl/aryl-2-[((6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinones derivatives (1-14)
To a suspension of 4-alkyl/aryl-1-[(6-(phenyl/4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl]-3-thiosemicarbazides (E1-14) (0.005 mol) in absolute ethanol (30 mL) were added anhydrous sodium acetate (0.02 mol) and ethyl bromoacetate/ethyl 2-bromopropionate (0.005 mol). The reaction mixture was refluxed for 5 h (for 1-4, 6-10 and 14) or 20 h (for 5, 11-13), then cooled, diluted with water and allowed to stand overnight. The crystals were filtered, dried and purified by crystallization from ethanol or ethanol/water. 
3-Phenyl-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (1)
UV
3-(4-Methylphenyl)-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (2)
3-(4-Chlorophenyl)-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (3)
3-Ethyl-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (4)
3-Propyl-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (5)
3-Allyl-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (6)
3-(4-Methylphenyl)-2-[((6-phenylimidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (8)
3-Phenyl-2-[((6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (14)
Biological activity
Antiviral activity
The compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were evaluated for activity against diverse RNA-and DNA-viruses, using the following cell-based assays [45] To perform the antiviral assays, the virus was added to subconfluent cell cultures in 96-well plates, and at the same time, the test compounds were added at serial dilutions. Appropriate reference compounds were included, i.e. the virus entry inhibitor dextran sulfate 5000, the broad antiviral agent ribavirin, the antiherpetic drug ganciclovir, and the HIV inhibitor azidothymidine. After 3-6 days incubation at 37 o C (or 35 o C in the case of influenza virus), the cultures were examined by microscopy to score the compounds' inhibitory effect on virus-induced cytopathic effect (CPE) or their cytotoxicity. For some viruses, antiviral and cytotoxic activities were confirmed by the colorimetric MTS cell viability assay [46] .
